MARKET

PULM

PULM

Pulmatrix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.100
-0.050
-4.35%
Opening 14:54 09/23 EDT
OPEN
1.120
PREV CLOSE
1.150
HIGH
1.240
LOW
1.090
VOLUME
845.54K
TURNOVER
--
52 WEEK HIGH
2.055
52 WEEK LOW
0.6103
MARKET CAP
37.85M
P/E (TTM)
-1.6902
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Pulmatrix Granted Canadian Patent Titled 'DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES'
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2809666/summary.html
Benzinga · 28m ago
Pulmatrix announces pipeline update
Pulmatrix ([[PULM]] -2.5%) update highlights:The company plans to commence patient dosing for PUR1800 Phase 1b trial in Q1 2021, and expects both the Phase 1b and 6-month toxicology data in
Seekingalpha · 23h ago
Pulmatrix Reports Progress On Product Pipeline
LEXINGTON, Mass., Sept. 22, 2020 /PRNewswire/ --Pulmatrix, Inc. (NASDAQ:PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and
Benzinga · 1d ago
Pulmatrix EPS beats by $0.33
Pulmatrix (NASDAQ:PULM): Q2 GAAP EPS of -$0.05 beats by $0.33. Revenue of $3.5M (-27.4% Y/Y) Press Release
seekingalpha · 08/07 18:09
Pulmatrix Reports Q2 2020 Results and Business Updates
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today reports its Q2 2020 financial results and pr
PR Newswire · 08/07 13:00
ALT, VERI, BBBY and MHK among midday movers
Seeking Alpha - Article · 07/09 16:39
Sensory Cloud to launch an OTC nasal hygiene product in September 2020
Seeking Alpha - Article · 07/08 13:38
Pulmatrix Announces Progress by Sensory Cloud Toward Commercial Launch of FEND in Fall 2020, an OTC Nasal Hygiene Product Designed to Suppress Exhaled Airborne Particles
PR Newswire · 07/08 13:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PULM. Analyze the recent business situations of Pulmatrix through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PULM stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 33
Institutional Holdings: 5.25M
% Owned: 15.27%
Shares Outstanding: 34.41M
TypeInstitutionsShares
Increased
6
2.60M
New
12
185.07K
Decreased
2
42.13K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.65%
Pharmaceuticals & Medical Research
-0.89%
Key Executives
Chairman/Independent Director
Michael Higgins
Chief Executive Officer/Director
Ted Raad
President/Chief Executive Officer/Director
Teofilo Raad
Vice President - Finance
Michelle Siegert
Director
Christopher Cabell
Independent Director
Rick Batycky
Independent Director
Mark Iwicki
Independent Director
Amit Munshi
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PULM
Pulmatrix, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing inhaled therapies to address serious respiratory disease. The Company designs and develops inhaled therapeutic products based on its dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways. iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with a broad range of drug substances including small molecules and biologics. The Company’s therapeutic candidates are Pulmazole, PUR1800, PUR5700, PUR3000 and PUR4000.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Pulmatrix Inc stock information, including NASDAQ:PULM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PULM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PULM stock methods without spending real money on the virtual paper trading platform.